Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial.
Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S. Torfoss D, et al. Among authors: tangen jm. J Antimicrob Chemother. 2007 Apr;59(4):711-7. doi: 10.1093/jac/dkm003. Epub 2007 Feb 27. J Antimicrob Chemother. 2007. PMID: 17327294 Clinical Trial.
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment.
Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S. Smeland KB, et al. Among authors: tangen jm. Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1735-9. doi: 10.4045/tidsskr.13.0319. Tidsskr Nor Laegeforen. 2013. PMID: 24005713 Free article. English, Norwegian.
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: tangen jm. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.
Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
Lenhoff S, Hjorth M, Westin J, Brinch L, Bäckström B, Carlson K, Christiansen I, Dahl IM, Gimsing P, Hammerström J, Johnsen HE, Juliusson G, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Tangen JM, Turesson I; Nordic Myeloma Study Group. Lenhoff S, et al. Among authors: tangen jm. Br J Haematol. 2006 May;133(4):389-96. doi: 10.1111/j.1365-2141.2006.06042.x. Br J Haematol. 2006. PMID: 16643445 Free article. Clinical Trial.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
Hellström-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, Löfvenberg E, Oberg G, Porwit-MacDonald A, Rådlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F; Scandinavian MDS Group. Hellström-Lindberg E, et al. Among authors: tangen jm. Br J Haematol. 2003 Mar;120(6):1037-46. doi: 10.1046/j.1365-2141.2003.04153.x. Br J Haematol. 2003. PMID: 12648074 Free article.
89 results